Propanc Biopharma is still a preclinical cancer-story equity more than a year after its Nasdaq uplisting, and the investment case now turns on whether a first-in-human protocol for its proenzyme candidate can outrun a capital structure that consumes more cash than the laboratory program does. The company has never generated product revenue. PRP remains an intravenous mix of trypsinogen and chymotrypsinogen that has not been dosed in patients despite nearly two decades of work. Cash at the March 2026 quarter-end was $443,702. The accumulated deficit sat at $140 million. That is the setup: a listing vehicle priced as a thin option on a still-untested mechanism.
What changed under the hood is not clinical de-risking. It is a financing and control redesign. An August 2025 underwritten sale priced one million shares at $4 and funded the uplisting. A Series C preferred facility marketed as a $100 million private placement has delivered only a few million of cash through mid-May. Meanwhile the board approved tens of millions of restricted shares for officers, directors, and vendors, and the chief executive's single Series B preferred share still confers majority voting power. Administration expense in the March quarter was $6.2 million, almost all noncash stock compensation. Research spending was $169,660. The laboratory is not where the money is going.
The market has already rendered a verdict on that mix. After a reverse split in May to chase the Nasdaq minimum bid, the equity closed mid-September at $0.61. That print implies a capitalization near $1.4 million on roughly two million post-split shares. The forward question is narrow. Does the Clinical Trial Application get filed and does first-patient dosing actually start, or does the Series C conversion and stock-for-services machine keep the story in the financing column?